Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Mar 1;366(9):844-6.
doi: 10.1056/NEJMe1115119.

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms

Ayalew Tefferi
Editorial

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms

Ayalew Tefferi. N Engl J Med. .
No abstract available

PubMed Disclaimer

Comment in

  • Ruxolitinib for myelofibrosis.
    Haznedaroglu IC. Haznedaroglu IC. N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704. N Engl J Med. 2012. PMID: 22621635 No abstract available.

Comment on

  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. Harrison C, et al. N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556. N Engl J Med. 2012. PMID: 22375970 Clinical Trial.
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.

LinkOut - more resources